Scilex Holding (SCLX) Other Accumulated Expenses (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Other Accumulated Expenses of $255000.0 for Q1 2026, down 99.85% year-over-year from $168.4 million in Q1 2025, and down 99.89% on a QoQ basis from $231.8 million in Q4 2025.
Scilex Holding (SCLX) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Other Accumulated Expenses for 7 consecutive years, with $255000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses fell 99.85% year-over-year to $255000.0; the TTM figure through Mar 2026 stood at $255000.0 (down 99.85% YoY), while the FY2025 annual figure was $231.8 million, changed N/A from the prior year.
- Other Accumulated Expenses came in at $255000.0 for Q1 2026 at Scilex Holding, down from $231.8 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $231.8 million in Q4 2025, with the low at $255000.0 in Q1 2026.
- Average Other Accumulated Expenses over 5 years is $93.4 million, with a median of $89.7 million recorded in 2023.
- Across the five-year window, Other Accumulated Expenses soared 984.25% in 2024 and sank 99.85% in 2026, its largest moves.
- Year by year, Other Accumulated Expenses stood at $30.9 million in 2022, then surged by 190.22% to $89.7 million in 2023, then jumped by 58.06% to $141.7 million in 2024, then jumped by 63.54% to $231.8 million in 2025, then plunged by 99.89% to $255000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $255000.0, $231.8 million, and $5.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 255,000.00 |
| Dec 31, 2025 | 231.76 Mn |
| Sep 30, 2025 | 5.74 Mn |
| Jun 30, 2025 | 192.94 Mn |
| Mar 31, 2025 | 168.43 Mn |
| Sep 30, 2024 | 141.71 Mn |
| Jun 30, 2024 | 125.06 Mn |
| Mar 31, 2024 | 104.09 Mn |
| Dec 31, 2023 | 89.66 Mn |
| Sep 30, 2023 | 65.80 Mn |
| Jun 30, 2023 | 47.78 Mn |
| Mar 31, 2023 | 9.60 Mn |
| Dec 31, 2022 | 30.89 Mn |
| Dec 31, 2021 | 7.36 Mn |
| Dec 31, 2020 | 25,760.00 |